Inulin supplementation in patients with infertility

Evaluation of inulin powder supplementation on sperm parameters, sex hormone levels, oxidative stress index, and inflammatory factors in idiopathic infertile men: A double-blind clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141025019669N22

Enrollment

Registered

2025-09-09

Start date

2025-10-23

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthenospermia. Male infertility

Interventions

Intervention 1: Intervention group: Inulin, 10 g per daily for three months, Manufacturer: Sensus. Intervention 2: Control group: Ten grams of maltodextrin powder daily for three months.

Eligibility

Sex/Gender

Male

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Willing to participate in the study Passing at least a year since the decision to child bearing (no conception after 12 months intercourse without any contraception) Age 20-45 y.o Idiopathic asthenospermia according to WHO criteria normal levels of gonadotropins , testosterone and prolactin

Exclusion criteria

Exclusion criteria: any infection in genitourinary (GU) tract any anatomical abnormality in GU tract such as varicocele, cryptorchidism and .... any chronic disease during last 3 months any surgery on the testes and vas deferens patients undergoing ICSI due to severe impairment sperm quality and the presence of other infertility factors contact with pesticides, heavy metals and solvents consumption of antioxidant supplements during last 3 months

Design outcomes

Primary

Measure	Time frame
Ejaculation volume. Timepoint: Before the intervention and after the intervention. Method of measurement: spermatogram.;Total sperm count. Timepoint: The beginning of the study , End of the study. Method of measurement: spermatogram.;Sperm motility. Timepoint: Before the intervention and after the intervention. Method of measurement: spermatogram.;Percentage of motile sperm. Timepoint: Before the intervention and after the intervention. Method of measurement: spermatogram.;Inflammatory factors. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Total antioxidant capacity. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Malondialdehyde. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Sex hormones. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.	—

Measure

Time frame

Ejaculation volume. Timepoint: Before the intervention and after the intervention. Method of measurement: spermatogram.;Total sperm count. Timepoint: The beginning of the study , End of the study. Method of measurement: spermatogram.;Sperm motility. Timepoint: Before the intervention and after the intervention. Method of measurement: spermatogram.;Percentage of motile sperm. Timepoint: Before the intervention and after the intervention. Method of measurement: spermatogram.;Inflammatory factors. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Total antioxidant capacity. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Malondialdehyde. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Sex hormones. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hozoori

Ghoum University of Medical Sciences

mhozoori@yahoo.com+98 25 3000 6207

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026